comparemela.com

Latest Breaking News On - Julien taieb - Page 1 : comparemela.com

Dr Taieb on the FDA Approval of TAS-102 Plus Bevacizumab in mCRC

Dr Taieb on the Safety Proline of TAS-102/Bevacizumab in Refractory mCRC

Dr Taieb on the Safety Proline of TAS-102/Bevacizumab in Refractory mCRC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

TAS-102/Bevacizumab Prolongs OS, PFS in Patients With mCRC and Maintained ECOG PS of 0 or 1

Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.

Dr Taieb on Findings from a Post-hoc Analysis of TAS-102 Plus Bevacizumab in Refractory mCRC

Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.

4,000 lives and €6bn saved by France s health pass claim economists

4,000 lives and €6bn saved by France s health pass claim economists
connexionfrance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from connexionfrance.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.